This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Bajaj Healthcare Q2 and H1 FY27 results: PAT up about 38 percent YoY
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited standalone results for Q2 and H1 FY27 (ended 30 Sept 2026). Q2 revenue from operations rose to Rs. 17,690.16 lakhs vs Rs. 14,791.49 lakhs YoY; H1 revenue Rs. 34,153.33 lakhs vs Rs. 29,675.12 lakhs. PAT from continuing operations Q2 was Rs. 1,437.98 lakhs vs Rs. 1,044.86 lakhs (about 38 percent higher YoY); H1 PAT Rs. 2,827.26 lakhs. Walker Chandiok issued an unmodified limited review. Board noted NCLT approval for Genrx Pharma acquisition, making it a wholly owned subsidiary.
Strong Q2 with healthy revenue growth and sharp PAT rise; Genrx acquisition to add a subsidiary. Positive for shareholders.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹175.9 Cr | ₹147.9 Cr | +18.9% |
| Operating profit | ₹17.58 Cr | ₹14.31 Cr | +22.9% |
| Profit after tax | ₹14.09 Cr | ₹11.11 Cr | +26.9% |
| EBITDA margin | 17.7% | 18.2% | −0.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.